C

Cutia Therapeutics
HKEX:2487

Watchlist Manager
Cutia Therapeutics
HKEX:2487
Watchlist
Price: 5.68 HKD -2.07% Market Closed
Market Cap: 1.8B HKD

Wall Street
Price Targets

Price Targets Summary
Cutia Therapeutics

Wall Street analysts forecast Cutia Therapeutics stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Cutia Therapeutics is 11.05 HKD with a low forecast of 8.08 HKD and a high forecast of 15.96 HKD.

Lowest
Price Target
8.08 HKD
42% Upside
Average
Price Target
11.05 HKD
95% Upside
Highest
Price Target
15.96 HKD
181% Upside
Cutia Therapeutics Competitors:
Price Targets
BAVA
Bavarian Nordic A/S
84% Upside
ZNTL
Zentalis Pharmaceuticals Inc
326% Upside
AMRN
Amarin Corporation PLC
32% Upside
086890
Isu Abxis Co Ltd
85% Upside
COYA
Coya Therapeutics Inc
166% Upside
002675
Yantai Dongcheng Biochemicals Co Ltd
3% Upside
HALO
Halozyme Therapeutics Inc
17% Upside

Revenue
Forecast

Revenue Estimate
Cutia Therapeutics

For the last 2 years the compound annual growth rate for Cutia Therapeutics's revenue is 396%. The projected CAGR for the next 3 years is 80%.

396%
Past Growth
80%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Cutia Therapeutics

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Cutia Therapeutics

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Cutia Therapeutics's stock price target?
Price Target
11.05 HKD

According to Wall Street analysts, the average 1-year price target for Cutia Therapeutics is 11.05 HKD with a low forecast of 8.08 HKD and a high forecast of 15.96 HKD.

What is Cutia Therapeutics's Revenue forecast?
Projected CAGR
80%

For the last 2 years the compound annual growth rate for Cutia Therapeutics's revenue is 396%. The projected CAGR for the next 3 years is 80%.

Back to Top